-
Novartis Pharmaceuticals Corporation et al v. Par Pharmaceutical Inc. DC CAFC
- 1:13-cv-01467
- D. Del.
- Judge: Richard G. Andrews
- Filed: 08/22/2013
- Closed: 09/17/2014
- Latest Docket Entry: 06/29/2015
- PACER
- Docket updated daily
5
Plaintiffs
1
Defendant
1
Accused
Product
1
Patent-in-Suit
392
Days in
Litigation
-
Novartis Pharmaceuticals Corporation et al v. Par Pharmaceutical Inc. DC CAFC
- 1:13-cv-01467
- D. Del.
- Judge: Richard G. Andrews
- Filed: 08/22/2013
- Closed: 09/17/2014
- Latest Docket Entry: 06/29/2015
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
3 |
A pharmaceutical composition according to claim 1 wherein the anti-oxidant is tocopherol, esters thereof, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole or propyl gallate.
|
Valid (103)
Entry 86 |
7 |
A transdermal device comprising a pharmaceutical composition as defined in claim 1, wherein the pharmaceutical composition is supported by a substrate.
|
Valid (103)
Entry 86 |
13 |
The transdermal device of claim 1, wherein the antioxidant is tocopherol, esters thereof, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole, or propyl gallate.
|
Valid (103)
Entry 86 |
16 |
A method according to claim 15, wherein the anti-oxidant is tocopherol, esters thereof, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole or propyl gallate.
|
Valid (103)
Entry 86 |
18 |
The method of claim 15, wherein the anti-oxidant is present in an amount of from about 0.01 to about 0.5% by weight based on the weight of the composition.
|
Valid (103)
Entry 86 |
-
Infringement
Par Pharmaceutical, Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
4.6 mg/24 hr, 9.5 mg/24 hr, and 13.3 mg/24 hr dosage strengths rivastigmine transdermal system | US 6,335,031 B1 | All Asserted Claims |
No infringement
Entry 86
|